Guilherme Nader Marta, MD, Institut Jules Bordet, Brussels, Belgium, comments on the need for personalized medicine for patients with triple negative breast cancer (TNBC). Due to TNBC being a heterogenous disease, targeted therapies have been beneficial additions to the treatment landscape for patients with TNBC. Findings potential biomarkers will additionally enable clinicians to identify patients who will benefit from innovative treatments. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
